Kinstellar has advised Neuraxpharm Group on the acquisition of Farmax from SVUS Pharma in the Czech Republic, Slovakia, and Hungary. BBH reportedly advised SVUS Pharma on the sale.
The terms of the transaction were not disclosed.
Farmax, located in Hradec Kralove, Czech Republic, is a central nervous system (CNS)specialty pharmaceutical company and a distributor of both branded and non-branded generics pharmaceuticals for CNS disorder in the Czech Republic, Slovakia, and Hungary. Farmax will be renamed Neuraxpharm Bohemia and will commercialize its products under the Neuraxpharm brand.
Neuraxpharm Group is a European specialty pharmaceutical company focused on the treatment of CNS disorders, and it is a part of the APAX portfolio group of companies.
Kinstellar’s team was led by Partner Lukas Sevcik and included Senior Associates Tereza Naucova and Adam Nemec, Associate Martin Holub, and Junior Associates Michal Matous, Tereza Maskova, and Vaclav Kment.
Editor’s Note: After this article was published BBH confirmed its involvement in the deal. The team was led by Partner Tomas Sedlacek, assisted by Senior Associate Alice Nytrova and Associate Ondrej Stanek.
